ViroGates A/S, an in vitro diagnostics company, develops and markets prognostic products for the healthcare sector. It offers suPARnostic, a proprietary biomarker used in hospital emergency services to support the clinical decision on hospitalization or discharge of acute patients and to identify high-risk sepsis patients at an early stage, as well as used for the prognosis of lifestyle-related diseases, such as cardiovascular disease, type 2 diabetes, and cancer; and for the assessment of longevity and biological age in a non-hospital setting. The company’ products icludes suPARnostic TurbiLatex, a latex particle-enhanced turbidimetric immunoassay that quantitatively determines the soluble urokinase plasminogen activator receptor (suPAR) level in human K2-EDTA- or lithium heparin plasma samples; suPARnostic ELISA that provides fully quantitative results; suPARnostic Quick Triage kit, which is used in the point of care situation for early warning and patient triaging that will allow clinicians and nurses to obtain a fast patient prognosis for patient disease severity, progression and outcome; and suPARnostic POC+, a point-of-care finger prick test that detects the level of suPAR in the blood. The company was founded in 2000 and is headquartered in Birkerød, Denmark.
तुलना करने के लिए मीट्रिक्स | VIROG | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधVIROGपीअर्सक्षेत्र | |
---|---|---|---|---|
पी/ई अनुपात | −7.8x | 10.2x | −0.6x | |
PEG अनुपात | −0.21 | 0.10 | 0.00 | |
क़ीमत/बुक | 14.6x | 5.7x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 14.3x | 4.4x | 3.2x | |
अपसाइड (विश्लेषक लक्ष्य) | - | 21.1% | 40.6% | |
उचित मूल्य अपसाइड | अनलॉक करें | 4.1% | 7.1% | अनलॉक करें |